BIO-KOREA
26.5.2021 15:02:11 CEST | Business Wire | Press release
As one of the most important global bio-health conventions, BIO KOREA 2021 International Convention has garnered great attention from home and abroad. To facilitate the discussion on the future bio-health industry in the ‘COVID-19 era’, the BIO KOREA 2021 to be held on June 9 to 21 will evolve around the theme of “New Normal: Breaking Barriers with Bio Innovation”.
BIO KOREA organizing committee announced the main programs, deep-diving into business strategies in the post-pandemic era.
The Four Programs Focusing on Biohealth Industry and Business
BIO KOREA 2021 Business Forum will focus on a virtual partnering system allowing attendees to schedule virtual meetings to maximize their business development and licensing potential.
International participation continues to grow. Numerous companies from 20+ countries already joined and are expected to showcase their advanced technologies at BIO KOREA 2021.
As an event involving various kinds of discussion, BIO KOREA attracts not only leading biohealth companies in Korea such as SK Chemicals, Chong Kun Dang, ShinPoong Pharm, Kolon Life Science, etc, but also promising SMEs like PharmCADD, WELT, Oncocross, Biot Korea, all of which are eager to grow their business. 24-hour meeting slots will strengthen your digital network across time zones. Also, company presentations will be livestreamed on the official BIO KOREA platform.
The Exhibition will be held both online and on-site, as a hybrid format, which will showcase the cutting-edge technologies and products of exhibitors in various ways. 300+ exhibitors, from start-up to global enterprise, will be at BIO KOREA’s exhibition. Participants can meet on-site exhibitors through live streaming on the online platform during the event.
There will be a Digital Healthcare-themed pavilion introducing the industrial rookies of Digital Wellness, Mobile Healthcare, Digital Therapeutics, Big Data, and AI, etc. Also, COVID-19 show room will show participants how biohealth serves as a cure for the pandemic.
The Conference of BIO KOREA will consist of valuable expert-level lectures regarding the most pressing industry topics including Digital Health, Drug Development, and Post COVID-19. BIO KOREA 2021 conference covering 18 topics with 170+ speakers, will bring the most up-to-date conversations of biohealth both online and on-site.
Invest Fair is an event where pharmaceuticals, bio, and healthcare companies that are advancing into the global market and developing new drugs introduce their leading technology, vision and strategy to the investors. Along with online hosting, it maintains the participants’ attendance with impressive lineups of 19 companies such as Lunit, Tium BIO, VaxcellBio and Genesystem.
BIO KOREA 2021 will be available both Online and On-site
BIO KOREA presents invaluable information on the industry’s trends around the world. This year, the global audience will have a front-row seat to discover and see the latest technology. All BIO KOREA programs will be livestreamed from June 9 to June 21. The program at a glance is on https://www.biokorea.org/program/schedule.asp .
For more updates: https://www.biokorea.org
About BIO KOREA
BIO KOREA serves as a venue place for practical business correspondence as well as international information and technology exchange, invigorating the bio industry. For 15 years, BIO KOREA has been a place of bringing together various international academics, professionals, and CEOs of global bio companies to obtain, exchange, and discuss diverse affairs. It has been providing abundant opportunities to enhance competitive edges within the convergence industry centered around biotechnology.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210526005412/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom